drugset / Trial / NCT03810742
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The study is to explore the combination of nal-IRI and TAS-102, which is expected to be an effective regimen that could be applied to various cancers
Timeline
- Start
- 2019-03-05
- Primary completion
- 2022-05-04
- Completion
- 2023-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | — |
| Subject | TAS-102 | Small molecule | — | — |